Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fulvestrant 3Everolimus 3Cetuximab 3PX-866 2Alpelisib 2venetoclax 1tivozanib 1tipifarnib 1serabelisib 1sapanisertib 1ribociclib 1pembrolizumab 1palbociclib 1neratinib 1exemestane 1cemiplimab 1abemaciclib 1Trimetazidine 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Docetaxel 1Capecitabine 1CB-839 1CA-4948 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hereditary Sensory and Autonomic Neuropathies × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡